Penault-Llorca F - Search Results

1

Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status.

Penault-Llorca F, Coudry RA, Hanna WM, Osamura RY, Rüschoff J, Viale G. Penault-Llorca F, et al. Breast. 2013 Apr;22(2):200-202. doi: 10.1016/j.breast.2012.12.004. Epub 2013 Jan 24. Breast. 2013. PMID: 23352656 Free article.

2

Current perspectives on HER2 testing: a review of national testing guidelines.

Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Rüschoff J, Tomasic G, van de Vijver M. Bilous M, et al. Mod Pathol. 2003 Feb;16(2):173-82. doi: 10.1097/01.MP.0000052102.90815.82. Mod Pathol. 2003. PMID: 12591971 Review.

3

Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.

Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, Ferrière JP, De Latour M, Chollet P. Penault-Llorca F, et al. Int J Oncol. 2003 Jun;22(6):1319-25. Int J Oncol. 2003. PMID: 12739000

4

[Assessment of HER2 status in breast cancer].

Penault-Llorca F, Cayre A. Penault-Llorca F, et al. Bull Cancer. 2004 Dec 1;91 Suppl 4:S211-5. Bull Cancer. 2004. PMID: 15899610 Free article. Review. French.

5

Standardization of HER2 testing: results of an international proficiency-testing ring study.

Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ. Dowsett M, et al. Mod Pathol. 2007 May;20(5):584-91. doi: 10.1038/modpathol.3800774. Epub 2007 Mar 30. Mod Pathol. 2007. PMID: 17396141 Free article.

6

Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy.

Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, Achard JL, Gimbergues P, Curé H, Chollet P. Tacca O, et al. Oncologist. 2007 Jun;12(6):636-43. doi: 10.1634/theoncologist.12-6-636. Oncologist. 2007. PMID: 17602055 Free article.

7

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification.

Cayre A, Mishellany F, Lagarde N, Penault-Llorca F. Cayre A, et al. Breast Cancer Res. 2007;9(5):R64. doi: 10.1186/bcr1770. Breast Cancer Res. 2007. PMID: 17908324 Free PMC article.

8

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.

van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F, Rüschoff J. van de Vijver M, et al. Breast Cancer Res. 2007;9(5):R68. doi: 10.1186/bcr1776. Breast Cancer Res. 2007. PMID: 17922920 Free PMC article.

9

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes.

Bidard FC, Matthieu MC, Chollet P, Raoefils I, Abrial C, Dômont J, Spielmann M, Delaloge S, André F, Penault-Llorca F. Bidard FC, et al. Ann Oncol. 2008 Jul;19(7):1261-1265. doi: 10.1093/annonc/mdn039. Epub 2008 Mar 5. Ann Oncol. 2008. PMID: 18325917 Free article.

10

Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.

Hanna WM, Hammond E, Taylor CR, Dabbs DJ, Penault-Llorca F, Bloom KJ, Bilous M, Badve S. Hanna WM, et al. Mod Pathol. 2008 Oct;21(10):1278-80; author reply 1280-1. doi: 10.1038/modpathol.2008.131. Mod Pathol. 2008. PMID: 18813329 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

505 results

Search Page

Filters